Thalidomide Patent Expiration
Thalidomide is Used for treating multiple myeloma and erythema nodosum leprosum. It was first introduced by Bristol-Myers Squibb Co
Thalidomide Patents
Given below is the list of patents protecting Thalidomide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Thalomid | US7230012 | Pharmaceutical compositions and dosage forms of thalidomide |
Dec 09, 2023
(Expired) | Bristol-myers |
| Thalomid | US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US6869399 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US7141018 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US7959566 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US7874984 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US7435745 | Methods and compositions for inhibition of angiogenesis |
Nov 03, 2017
(Expired) | Bristol-myers |
| Thalomid | US5629327 | Methods and compositions for inhibition of angiogenesis |
May 13, 2014
(Expired) | Bristol-myers |
| Thalomid | US6235756 | Methods and compositions for inhibition of angiogenesis by thalidomide |
Mar 01, 2013
(Expired) | Bristol-myers |
| Thalomid | US7723361 | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide |
Mar 01, 2013
(Expired) | Bristol-myers |
| Thalomid | US8143283 | Methods for treating blood-born tumors with thalidomide |
Mar 01, 2013
(Expired) | Bristol-myers |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Thalidomide's patents.
Latest Legal Activities on Thalidomide's Patents
Given below is the list recent legal activities going on the following patents of Thalidomide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 17 Jul, 2023 | US7959566 |
| Expire Patent Critical
| 27 Feb, 2023 | US7874984 |
| Maintenance Fee Reminder Mailed Critical
| 30 Jan, 2023 | US7959566 |
| Maintenance Fee Reminder Mailed Critical
| 12 Sep, 2022 | US7874984 |
| Expire Patent Critical
| 16 Nov, 2020 | US7435745(Litigated) |
| Maintenance Fee Reminder Mailed Critical
| 01 Jun, 2020 | US7435745(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Dec, 2018 | US7959566 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Dec, 2018 | US7230012(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jul, 2018 | US7874984 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 May, 2018 | US7141018 |
Thalidomide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Thalidomide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Bevacizumab in the Treatment of HHT | Second Affiliated Hospital, Zhejiang University, School of Medicine | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | Memorial Sloan Kettering Cancer Center | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE2 |
| Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis | Air Force Military Medical University, China | NA |
COMPLETED
(Mar 1, 2026)
| PHASE3 |
| Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. | Yongquan Shi | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |